PD-L1 Protein (AA 19-239)

N° du produit ABIN7938682

Cette protéine Recombinant PD-L1 est exprimée dans Baculovirus infected Insect Cells.

Aperçu rapide pour PD-L1 Protein (AA 19-239) (ABIN7938682)

Antigène: PD-L1 (CD274 (PD-L1))

Type de proteíne: Recombinant

Origine: Humain

Source: Baculovirus infected Insect Cells

Application: Screening Assay (ScA), Activity Assay (AcA), Functional Studies (Func)

Détail du produit

Attributs du protein: AA 19-239

Fonction: Recombinant PD-L1 / CD274 (19-239) protein

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Recombinant PD-L1 / CD274 (19-239) protein is supplied in 25 mM HEPES-NaOH pH 7.5, 300 mM NaCl, 10 % glycerol, 0.04 % Triton X-100, 0.5 mM TCEP.

Conseil sur la manipulation: Avoid repeated freeze/thaw cycles,keep on ice when not in storage

Stock: -80 °C

Stockage commentaire: Recombinant proteins in solution are temperature sensitive and must be stored at -80°C to prevent degradation. Avoid repeated freeze/thaw cycles and keep on ice when not in storage.

Détail du antigène

Antigène: PD-L1 (CD274 (PD-L1))

Autre désignation: PD-L1 & CD274

Sujet:

Protein Background: PD-L1 is a ligand that binds with the receptor PD1, commonly found on T-cells, and acts to block T-cell activation. It plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/PD-1, PD-L1 modulates the activation threshold of T-cells and limits T-cell effector response. Through a yet unknown activating receptor, PD-L1 may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10). The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival. The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function. The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy.

Short Description: Recombinant PD-L1 / CD274 (19-239) protein that includes amino acids 19-239 of human PD-L1 protein (accession number NP_054862.1) was expressed in a baculovirus expression system, and contains an C-terminal FLAG tag. The molecular weight of the protein is 27.1 kDa.

Aliases: B7-H1

Pathways: Cancer Immune Checkpoints